Over 1,000 adverse event reports — and counting
If you've noticed your ponytail getting thinner since starting Ozempic, Wegovy, or Mounjaro, you're looking at one of the most-discussed side effects in the GLP-1 conversation right now. And the numbers back you up.
A 2025 systematic review by Dr. Omar Alsuwailem and colleagues pooled data from five studies covering 2,905 patients on GLP-1 receptor agonists. Their findings were mixed — some patients experienced hair regrowth, others lost hair — but the pharmacovigilance data tells a clearer story about risk.
Dr. Hannah Godfrey at the University of Arizona analyzed the FDA Adverse Event Reporting System (FAERS) from 2022 to 2023 and found that semaglutide carried a reporting odds ratio (ROR) of 2.46 for alopecia (95% CI: 2.14-2.83). Tirzepatide came in at an ROR of 1.73 (95% CI: 1.42-2.09). Other GLP-1 drugs — dulaglutide, liraglutide, exenatide — showed no statistically significant signal.
A reporting odds ratio above 1.0 means a drug is reported for a side effect more than expected. An ROR of 2.46 means semaglutide appears in alopecia reports roughly 2.5 times more often than the average medication in the FAERS database.
The Wegovy FDA prescribing label puts concrete percentages on it: across three randomized, double-blind trials involving 2,116 adults, hair loss occurred in 3% of Wegovy-treated patients compared to 1% on placebo. In a separate pediatric trial, the gap was starker — 4% on Wegovy versus 0% on placebo.
Tirzepatide's SURMOUNT-1 trial, published by Dr. Ania Jastreboff in the New England Journal of Medicine, reported alopecia rates between 4.9% and 5.3% across its three dose groups, compared to 0.9% on placebo. That five-fold difference is hard to dismiss.
A separate analysis by Nakhla et al. queried four international pharmacovigilance databases — FAERS, the Australian DAEN, EudraVigilance, and the WHO's VigiBase — and found that GLP-1 receptor agonists were the most-reported drug class for hair loss among all diabetes medications. Semaglutide, liraglutide, and dulaglutide topped the list. The signal didn't meet their strict threshold for a formal disproportionality alert (which required both PRR >2 and chi-squared >4 simultaneously), but the volume of reports was enough for the authors to call for "intensive monitoring."
Novo Nordisk has acknowledged this. The Wegovy product monograph lists alopecia as an identified adverse event, and Burke et al.'s 2025 retrospective study at the University of Miami calculated an odds ratio of 6.97 for hair loss specifically with semaglutide.
Your hair isn't falling out — it's being pushed out early
To understand what's happening on your scalp, you need a 30-second crash course in hair biology. Think of your hair follicles as a factory running three shifts. The growth shift (anagen) lasts up to four years and employs about 85% of your follicles at any given time. The transition shift (catagen) is brief. The shedding shift (telogen) normally involves just 5-10% of your hair, which is why you typically lose about 100 strands a day and never notice.
Telogen effluvium flips those ratios. A physical stressor — surgery, illness, childbirth, or rapid weight loss — sends a mass resignation notice to your growth-phase follicles. Up to 70% of anagen hairs can prematurely enter the telogen phase, and two to three months later, they all fall out around the same time. Daily shedding can jump to 300 strands.
The bariatric surgery literature has documented this pattern for decades. A case report and review by Dr. Rena Cohen-Kurzrock and Dr. Philip Cohen describes a 24-year-old woman who developed diffuse hair loss just seven weeks after gastric sleeve surgery. Her blood work was normal — no iron deficiency, no vitamin problems. The surgery itself, and the rapid metabolic shift it triggered, was the stressor. Her hair recovered fully within 14 months.
This is the pattern most dermatologists suspect with GLP-1s. The weight loss these drugs produce — often 15-20% of body weight — creates the same metabolic shock as bariatric surgery, minus the scalpel. Novo Nordisk's own data supports the dose-response relationship: among patients on Wegovy who lost more than 20% of their body weight, 5.3% developed alopecia, compared to 2.5% among those who lost less than 20%.
If your hair starts thinning three to four months after beginning a GLP-1 and you've been losing weight rapidly, telogen effluvium is the most likely explanation. And in 95% of acute cases, it resolves on its own once the trigger stabilizes — typically within six to eight months.
The paradox: GLP-1 receptors on hair follicles might help hair grow
This is where the research gets contradictory. While pharmacovigilance databases flag semaglutide for hair loss, there's a parallel line of research suggesting GLP-1 signaling might actually support hair growth.
In 2006, Dr. Joel Habener's lab at Massachusetts General Hospital and Harvard Medical School discovered that GLP-1 receptors are expressed in mouse skin — specifically concentrated in the hair follicles. When they exposed cultured skin cells to GLP-1, it activated the MAPK/ERK signaling pathway, which is associated with cell proliferation, differentiation, and cytoprotection. The researchers proposed that GLP-1 might play a role in folliculogenesis (the formation and cycling of hair follicles) through a paracrine or autocrine mechanism.
Think of it like discovering that a weight loss drug also happens to fertilize the soil where hair grows. The drug is potentially doing both things simultaneously — causing rapid weight loss that triggers telogen effluvium while also directly stimulating the biological machinery of hair follicles.
Clinical observations support this duality. The Alsuwailem systematic review found three studies where tirzepatide actually improved hair regrowth. One case involved androgenic alopecia, another folliculitis decalvans, and a third central centrifugal cicatricial alopecia. In the androgenic alopecia case, a patient experienced significant hair regrowth and increased hair density after one year on tirzepatide.
There may also be an indirect mechanism at work. Dr. Diala Haykal noted that GLP-1 receptor agonists can cause thyroid hormone fluctuations, and even subtle changes in thyroid function can disrupt hair follicle cycling. Semaglutide has separately been flagged for potential hormonal effects that could increase the risk of androgenic alopecia — a pattern that might persist even after discontinuation.
Researchers haven't untangled this yet. The weight loss effect (telogen effluvium) and any direct drug effects on follicles are happening at the same time in the same patients, making it difficult to isolate one from the other. What we can say: the majority of hair loss reported with GLP-1s follows the classic telogen effluvium timeline and pattern.
The nutrient gap GLP-1s can quietly create
There's a third factor compounding the hair loss picture, and it's the one you have the most control over.
GLP-1 drugs work partly by suppressing appetite and slowing gastric emptying. That reduced food intake, combined with the gastrointestinal side effects (73% of Wegovy-treated adults reported GI adverse reactions including nausea, vomiting, and diarrhea), can drain your nutrient reserves faster than you'd expect. You're eating less, absorbing less, and losing weight fast — all while your hair follicles are demanding raw materials to maintain their growth cycle.
Hair follicles are among the most metabolically active structures in the body. The matrix cells in the follicle bulb divide rapidly and require a steady supply of proteins, iron, zinc, and vitamins. When those supplies run short, hair is one of the first things the body deprioritizes — it's not essential for survival, so the follicles go dormant.
A comprehensive review by Dr. Antonella Tosti's team at the University of Miami mapped the specific nutrients linked to hair loss:
| Nutrient | Role in hair health | Evidence for supplementation |
|---|---|---|
| Iron | Supports cellular turnover in follicle matrix cells | Strong — recommended if deficient in AGA or TE |
| Vitamin D | Involved in hair follicle cycling and immune function | Moderate — supplementation improves AGA and TE when levels are low |
| Zinc | Required for protein synthesis and cell division | Insufficient evidence to recommend routinely |
| Biotin (B7) | Cofactor for carboxylases in amino acid metabolism | Weak — deficiency is rare; supplementation not supported for AGA/TE |
| Vitamin C | Enhances intestinal iron absorption | Recommended alongside iron supplementation |
| Protein | Essential building block for keratin production | Strong — 40-60g/day minimum recommended |
The bariatric literature offers a useful preview of what GLP-1 patients may face. Cohen-Kurzrock and Cohen found that nutritional deficiencies occur in roughly half of bariatric surgery patients, and these deficiencies are a distinct cause of hair loss that typically appears later — around six months post-surgery — compared to the three-month timeline for telogen effluvium.
There's also a counterintuitive risk with over-supplementation. Tosti's review established that excessive vitamin A intake (above 10,000 IU per day of preformed vitamin A) can itself trigger telogen effluvium. More is not always better when it comes to hair supplements.
If you're experiencing hair changes alongside significant weight loss on a GLP-1, getting your levels checked — specifically ferritin, iron, vitamin D, zinc, and thyroid function — is a more productive step than blindly loading up on hair growth gummies. The information on which supplements actually help (and which are marketing) might surprise you, and it overlaps with guidance on key supplements to take while on GLP-1 medications.
What actually works — and what doesn't
The gap between what works and what sells is wide.
Minoxidil (Rogaine)
A 2025 clinical trial led by Dr. Manabu Ohyama tested 5% topical minoxidil on 12 patients with telogen effluvium (from various triggers including crash dieting). Terminal hair count increased by 12.55 hairs per square centimeter within just four weeks. By week 24, 100% of subjects showed at least some improvement, and 80% were rated "moderately improved" or better by the dermatologists evaluating them.
This is technically off-label — minoxidil is approved for androgenetic alopecia, not TE. But the mechanism makes sense: minoxidil opens potassium channels in the dermal papilla, improving blood flow and stimulating vascular endothelial growth factor (VEGF) production. It essentially nudges resting follicles back into the growth phase faster than they'd recover on their own.
One important caveat: TE generally resolves on its own. This trial had no placebo control, so it's impossible to separate minoxidil's effect from natural recovery. Still, for patients experiencing significant distress from hair shedding, the safety profile is well-established and the early improvement (week 4-8) may reduce the anxiety of watching hair fall out for months.
Biotin supplements
Evidence and marketing diverge sharply on this one. Despite biotin being the star ingredient in most "hair growth" supplements, Tosti's comprehensive review found that biotin supplementation is not supported by the literature for treating either androgenetic alopecia or telogen effluvium. True biotin deficiency is rare in people eating a normal diet — the only convincing case reports involve children with genetic biotinidase deficiency or adults on medications that interfere with biotin metabolism.
Worse, high-dose biotin can interfere with laboratory tests. The FDA issued a safety warning after biotin supplements caused a falsely low troponin result that led to a missed heart attack diagnosis and a patient's death. Biotin interference has been documented in thyroid tests, hormone panels, and tumor markers — ironically, exactly the tests you'd want accurate readings on while taking a GLP-1.
Iron supplementation
If blood work shows low ferritin or iron, supplementation has the strongest evidence base. Tosti's review recommends iron supplementation for patients with AGA or TE who have confirmed low iron levels (more commonly seen in women). Pair it with vitamin C to enhance absorption.
Vitamin D
Several studies found that supplementing low vitamin D levels improved symptoms of both androgenetic alopecia and telogen effluvium. If your levels are below the normal range, this is worth correcting — and vitamin D deficiency is common enough in the general population that many GLP-1 patients likely have it even before starting medication.
Six steps to protect your hair while staying on track
None of the research suggests hair loss is a reason to stop GLP-1 therapy — the cardiovascular, metabolic, and weight management benefits are substantial. But you can take specific steps to minimize the impact. If you've noticed facial changes from weight loss alongside hair thinning, that combination is common and addressed in our guide on Ozempic face.
| Step | What to do | Why it matters |
|---|---|---|
| 1. Prioritize protein | Aim for 40-60 grams daily minimum, even when appetite is suppressed | Hair is made of keratin (a protein). Protein-deficient diets are a recognized TE trigger |
| 2. Get blood work | Test ferritin, iron, vitamin D, zinc, and thyroid function before or early in treatment | Identifies correctable deficiencies before hair loss becomes visible |
| 3. Supplement strategically | Iron + vitamin C if ferritin is low; vitamin D if below normal range | Evidence-based corrections, not scattershot supplementation |
| 4. Moderate the weight loss pace | Work with your prescriber on dosing; slower titration may help | Hair loss correlates with speed of weight loss — 5.3% alopecia with >20% loss vs 2.5% with <20% |
| 5. Consider topical minoxidil | 5% solution applied twice daily if shedding is significant | May accelerate recovery from telogen effluvium (off-label but well-tolerated) |
| 6. Skip high-dose biotin | Standard multivitamin doses are fine; avoid megadose biotin supplements | No proven benefit for TE; can cause dangerous false lab results |
The timing matters too. If you're going to lose hair on a GLP-1, it will most likely happen in the first three to six months as your body adjusts to the rapid metabolic changes. After that initial period, as weight loss slows and your body reaches a new equilibrium, the shedding typically stops and regrowth begins. Some patients report seeing noticeable new growth by months eight to twelve.
If your hair loss doesn't follow the classic TE pattern — if it's patchy rather than diffuse, if it starts at the crown or temples specifically, or if it continues beyond a year — see a dermatologist. Those patterns suggest androgenetic alopecia or another condition that requires different treatment.
Frequently Asked Questions
Does Ozempic cause hair loss, or is it the weight loss?
Most evidence points to the rapid weight loss rather than a direct drug effect. Novo Nordisk's own data shows alopecia rates double in patients who lose more than 20% of body weight compared to those losing less. The same pattern occurs after bariatric surgery without any GLP-1 involvement. That said, semaglutide's reporting odds ratio of 2.46 for alopecia is higher than what weight loss alone might explain, and researchers haven't fully ruled out a direct pharmacological effect.
Will my hair grow back after stopping semaglutide or tirzepatide?
In most cases, yes. Telogen effluvium is temporary by definition — acute TE resolves in 95% of cases once the triggering stressor stabilizes. You don't necessarily need to stop the medication; most patients see their hair recover as weight loss slows and their body adapts, typically within six to twelve months of onset. The bariatric surgery literature confirms this pattern: hair loss is common post-procedure but almost always reverses.
Should I take biotin for GLP-1-related hair loss?
Probably not at megadoses. A comprehensive review by Dr. Antonella Tosti's group found that biotin supplementation is not supported by the evidence for treating telogen effluvium or androgenetic alopecia. Biotin deficiency is rare in anyone eating a normal diet. More concerning, high-dose biotin supplements can interfere with lab tests for thyroid function, troponin, and other markers — the FDA issued a safety warning after a patient died from a missed heart attack diagnosis caused by biotin interference. A standard multivitamin provides adequate biotin without these risks.
What blood tests should I ask for if my hair is thinning on a GLP-1?
Ask your provider to check ferritin, serum iron, vitamin D (25-hydroxy), zinc, and a thyroid panel (TSH, free T3, free T4). The bariatric surgery literature recommends also checking calcium, folate, and vitamins A, B1, B6, and B12 in patients with rapid weight loss. Correcting any identified deficiency is the most evidence-based intervention available.
Is hair loss more common with semaglutide or tirzepatide?
FAERS data shows semaglutide has a higher reporting odds ratio for alopecia (2.46) than tirzepatide (1.73), according to Godfrey et al.'s disproportionality analysis. However, tirzepatide's clinical trial (SURMOUNT-1) reported higher absolute alopecia rates (4.9-5.3%) compared to Wegovy's trials (3%). The discrepancy may reflect different patient populations, weight loss magnitudes, or reporting patterns rather than a true difference in drug-specific risk.
Medical Disclaimer
This article is for informational and educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare professional regarding any medical concerns. Never ignore professional medical advice or delay seeking care because of something you read on this site. If you think you have a medical emergency, call 911 immediately.
